Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36) Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14) Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16) Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23) CME information and select publications

Featuring perspectives from Dr Richard F Riedel, including the following topics: Introduction: (0:00) Case: A woman in her late 20s with multiregimen-recurrent metastatic alveolar soft part sarcoma after treatment with multiple VEGF tyrosine kinase inhibitors and a single-agent PD-1 inhibitor receives axitinib/pembrolizumab — Nam Bui, MD (4:14) Case: A man in his mid 60s with metastatic dedifferentiated chondrosarcoma of the right femur undergoes resection and receives doxorubicin/cisplatin followed by maintenance pembrolizumab — IDH2 and TERT promoter mutations, PD-L1 2+ by IHC — Melanie B Thomas, MD (10:06) Case: A man in his early 30s with an asymptomatic "bulge on abdomen" found to be a 6.2-cm mass receives a diagnosis via biopsy of desmoid fibromatosis. Local treatment team recommends surgery — Dr Bui (22:20) Case: A woman in her early 40s with a history of familial adenomatous polyposis undergoes surgical excision of 3 colon cancer lesions followed by adjuvant capecitabine. On follow-up she is found to have a rapidly enlarging mass abutting the iliac and mesenteric vessels. Fine needle aspiration shows desmoid tumor — Dr Bui (29:37) Case: A man in his mid 30s with a protruding mass on his back diagnosed as a desmoid tumor receives sorafenib followed by second-line liposomal doxorubicin — Atif M Hussein, MD, MMM (33:29) Case: A man in his mid 50s with multiregimen-recurrent metastatic mediastinal liposarcoma receives resection, chemotherapy and eribulin — CDK4 amplification identified by next-generation sequencing (NGS) — Dr Thomas (39:31) Case: A man in his late 60s with abdominal pain and weight loss is diagnosed with metastatic high-grade myxoid liposarcoma of the retroperitoneum — Dr Hussein (43:06) Case: A woman in her late 50s diagnosed with Grade 2 leiomyosarcoma develops a recurrence 3 years after resection and adjuvant doxorubicin/ifosfamide — Dr Hussein (47:34) Case: A woman in her early 60s presents to the ER with shortness of breath and is diagnosed with unresectable leiomyosarcoma of the mediastinum — Dr Bui (51:48) Case: A man in his mid 40s diagnosed with gastrointestinal stromal tumor (GIST) receives neoadjuvant imatinib followed by resection, then adjuvant imatinib — KIT exon 9 mutation identified by NGS — Dr Bui (54:13) Case: A man in his mid 60s with mesenteric recurrence of abdominal GIST experiences transaminitis with imatinib — microsatellite stable, no actionable mutations by NGS — Dr Thomas (58:40) CME information and select publications

Featuring an interview with Dr Jeremy Abramson, including the following topics: Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00) Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31) Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21) Available data with bispecific antibodies for CLL (9:38) Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09) Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25) CD20 versus CD19 as a therapeutic target in lymphomas (20:31) First-line treatment selection for patients with mantle cell lymphoma (23:07) Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12) CME information and select publications

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics: Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00) Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and GLOW trials (5:27) Primary analysis of the TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for relapsed/refractory (R/R) CLL (12:40) Genomic evolution and resistance to pirtobrutinib in patients with covalent BTK inhibitor-pretreated CLL in the Phase I/II BRUIN study (16:24) Chimeric antigen receptor (CAR) T-cell therapy data with axicabtagene ciloleucel and lisocabtagene maraleucel for R/R follicular lymphoma (FL) (18:24) Bispecific antibodies as treatment for R/R FL: mosunetuzumab, epcoritamab, odronextamab and TNB-486 (22:57) Novel treatment approaches for mantle cell lymphoma (MCL): First-line acalabrutinib/rituximab and lisocabtagene maraleucel for R/R disease (32:54) Updated results from studies evaluating loncastuximab tesirine, such as LOTIS-2, and CAR T-cell therapy, such as TRANSFORM and ZUMA-7, for R/R diffuse large B-cell lymphoma (39:29) Ongoing follow-up from pivotal trials of bispecific antibodies for large B-cell lymphomas (46:01) SWOG-S1826: Results from the Phase III trial evaluating nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) versus brentuximab vedotin with AVD for advanced-stage classic Hodgkin lymphoma (51:48) CME information and select publications

Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer (0:00) Renal Cell Carcinoma (22:58) Urothelial Bladder Cancer (52:18) CME information and select publications

Featuring perspectives from Dr Adiyta Bardia and Dr Erika Hamilton, including the following topics: Introduction: Biopharmacology and Endocrinology of Breast Cancer (0:00) Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Dr Bardia (12:15) Future Directions in the Management of ER-Positive mBC — Dr Hamilton (33:16) Clinical Investigator Survey (51:50) CME information and select publications

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 2: Future Directions in the Management of ER-Positive mBC — Erika Hamilton, MD CME information and select publications

Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor | Faculty Presentation 1: Current Strategies for Previously Treated ER-Positive Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Saad Zafar Usmani, including the following topics: Introduction (0:00) Biology/Immunology; Overview (3:05) Current Available Data (19:40) Clinical Investigator Survey (33:11) Combinations/Ongoing Trials (55:40) CME information and select publications

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 1: Available Data with and Potential Clinical Role of Bispecific Antibodies for Multiple Myeloma (MM) CME information and select publications